Adalimumab-induced systemic lupus erythematosus: A case report and review of the literature

Adalimumab is a tumor necrosis factor inhibitor that has been widely used since the early 2000s for the treatment of psoriasis and psoriatic arthritis. All tumor necrosis factor inhibitors have been identified as causative agents in drug induced lupus, particularly etanercept and infliximab. There h...

Full description

Saved in:
Bibliographic Details
Published in:SAGE open medical case reports 2023-01, Vol.11, p.2050313X231193077
Main Authors: Landells, Fiona M, Vender, Ronald
Format: Article
Language:English
Subjects:
JCMS Case Report
Lupus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adalimumab is a tumor necrosis factor inhibitor that has been widely used since the early 2000s for the treatment of psoriasis and psoriatic arthritis. All tumor necrosis factor inhibitors have been identified as causative agents in drug induced lupus, particularly etanercept and infliximab. There have been few reported cases of systemic lupus erythematosus induced by adalimumab, many more are attributable to treatment with etanercept or infliximab. We present the case of a patient with long-standing psoriasis and psoriatic arthritis who was successfully treated with adalimumab, but developed anti-tumor necrosis factor-induced lupus.
ISSN:2050-313X
2050-313X
DOI:10.1177/2050313X231193077